NCT04430192 assesses the safety, effectiveness, and appropriate dosage of 177Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer undergoing radical prostatectomy and pelvic lymph node dissection. Here, FOLH1 is linked to prostate carcinoma.